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INTRODUCTION

B
enign lymphoepithelial lesion (BLEL) [1] , also referred to as Mikulicz disease [2] , is a relatively rare disease, with the major clinical manifestations being symmetrical and painless enlargement of the bilateral lacrimal glands and/ or the salivary glands [3] [4] . The cause and pathogenesis of BLEL remain unclear. Clinically, BLEL can be treated with glucocorticoid therapy, but glucocorticoid resistance is a frequent occurrence [5] . Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine first identified in 1966 during studies of the delayed-type hypersensitivity reaction and characterized as a soluble product of activated T lymphocytes that inhibits macrophage migration in vitro [6] [7] . MIF has been shown to act as a critical mediator of host defence with a role in septic shock and chronic inflammatory and autoimmune diseases [8] [9] . Furtherly, MIF has the unique ability to override the inhibitory effects of glucocorticoid on the immune system [10] [11] . MIF gene is located in chromosome 22 (22q11.2) and contains two clinically relevant polymorphisms within the promoter region that have been associated with susceptibility to several diseases [12] [13] [14] [15] [16] . A short tandem repeat (STR) polymorphism is located at locus -794 (rs5844572), which is a microsatellite repetition of cytosine-adenine-thymine-thymine (CATT), and the repeat length (5 to 8 repetitions) which correlates with increased gene expression and with circulating MIF levels [12] . Likewise, the single nucleotide polymorphism (SNP) -173 G>C MIF (rs755622) has been found at location -173 of the MIF gene with a change from guanine (G) to cytosine (C). Similar to the functions of STR polymorphism above, this -173*C allele is also reported to associated with mRNA expression and circulating MIF levels [17] . More fundamentally, some studies indicated that MIF-173G/C gene polymorphism may increase the risk of glucocorticoid resistance in a series of diseases including juvenile arthritis, nephrotic syndrome and colitis [18] [19] [20] . In this study, we evaluated the association of the -794 CATT (5) (6) (7) (8) and -173G>C MIF polymorphisms with glucocorticoid susceptibility to lacrimal gland BLEL. SUBJECTS AND METHODS Participants or Samples A total of 40 patients with lacrimal gland BLEL were registered and treated at the Beijing Tongren Hospital between September 2013 and April 2016. The study population comprised 11 males and 29 females, the ages ranged from 23 to 63y with a median age of 47y. The enlargement of the lacrimal in patients with BLEL was found to be uncongested and symmetric or unilateral as well as asymptomatic and nontender to palpation. All BLEL diagnosis was confirmed by post-surgical histological examinations. Forty subjects with healthy subjects (HS) were recruited as a control group comprised of 20 male and 20 female subjects, aged between 29 and 64y. Peripheral blood samples of 40 patients with lacrimal gland BLEL and 40 HS from Beijing Tongren Hospital and University Hospital of Beijing University of Technology are prepared for this trial. The study protocol was approved by the Ethics Committee of Beijing University of Technology and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants before their enrollment (Table 1) . Pretreatments Whole blood was centrifuged at 2000 rpm for 10min; the upper layer was then carefully removed into a clean tube and stored at -20℃ ; whole blood DNA was at last extracted from the left blood cells by using Genomic DNA Extraction from blood system (TIANGEN ® China).
Genotyping of the SNP-173G>C and STR -794 CATT (5-8) Polymorphism
To analyze the SNP-173G>C MIF polymorphism, we amplified polymorphic fragments by conventional polymerase chain reaction (PCR). Amplification of a 497 bp fragment was completed using the primers as follows: forward primer 5'-CCCCGC CCC ATC TCA AAC ACA-3' and reverse primer 5'-CCGCCG CTG AGC TAC GTG CC-3'. Cycling conditions were as follows: initial denaturing at 94℃ for 5min followed by 30 cycles of 30s at 94℃ , 30s at 58℃ , and 30s at 72℃ and then a final extension of 5min at 72℃ . The -794 CATT (5) (6) (7) (8) MIF polymorphism was analyzed by conventional poly merase chain reaction (PCR) and amplification of a 346 bp fragment was completed using the primers as follows: forward primer 5'-TGCAGGAACCAATACCCATAG G-3' and reverse primer 5'-AATGGTAAACTCGGGGAC-3'. Of 30 cycles and an annealing temperature of 58℃ were used. (5) (6) (7) (8) and the morbidity risk rate of lacrimal gland BLEL ( Table 2 ). The MIF level in plasma was significantly higher in patients of lacrimal gland BLEL (mean 11.07 ng/mL, range 2.01-33.41 ng/mL) versus HS (mean 1.71 ng/mL, range 0.98-2.71 ng/mL) (P<0.001; Figure 1 ). As shown in Figure 2 , a total of 40 patients with lacrimal gland BLEL were genotyped for the -173 polymorphism of the MIF gene and evaluated for MIF levels in plasma. We found that patients carrying the MIF-173*C allele had higher MIF levels of serological MIF, which were significantly higher than those of patients with the GG genotype (P=0.0041). Although the plasma level of MIF in patients with MIF-794 CATT (7/x) was elevated, but no significant difference was observed.
DISCUSSION
Lacrimal glands BLEL is characterized by unilateral or symmetric bilateral swelling of the lacrimal glands, the etiology and pathogenesis of which, remain ill defined, is relatively less studied over the last decade.
In this study, we investigated the association of -173G>C MIF and -794 CATT (5) (6) (7) (8) MIF polymorphism with the risk of BLEL of lacrimal gland in Beijing population. The patients with BLEL in this study were mainly middle-aged females with a male-to-female ratio of 1:3. The median age was 47y (range 23-63y). The enlargement of the lacrimal in patients with BLEL was found to be uncongested as well as asymptomatic and nontender to palpation. We found that -173 G to C mutations located in promoter region might be a potential risk factor. However, we did not find a significant association between -794 CATT (5) (6) (7) (8) MIF polymorphism with the risk of BLEL of lacrimal gland. MIF-173 G to C mutations are increasingly recognized causes of immune-system disorders, including acute myeloid leukemia, erythema nodosum and psoriatic arthritis [21] [22] [23] . We found the similar situation in BLEL of lacrimal gland. Besides, we found that the carriage rate of the MIF -173C/x was related to higher plasma levels of MIF in the BLEL of lacrimal gland. There were already massive evidences that elevated MIF overcomes the inhibitory effects of glucocorticoids on TNFalpha, IL-6 and IL-8 production, restores IL-2 and IFN-gamma production, and antagonizes the glucocorticoid inhibition of the production of several enzymes and cell surface molecules [24] . However, glucocorticoid therapy is the main method of drug treatment in the BLEL of lacrimal gland. In line with this, higher carried allele MIF -173C and higher plasma levels of MIF in patients with BLEL of lacrimal gland were consistent with poorer response to glucocorticoid treatment, with a higher risk of local recurrence. Thereby, the detection of MIF -173G/ C polymorphism could be a good index that can determine the CATT (5/5, 5/6, 6/6) or to the allele frequencies of MIF-794 CATT (7/x) , P>0.05.
Comparison among groups was performed using Mann-Whitney U test.
curative effect of glucocorticoid therapy in BLEL of lacrimal gland. In summary, we investigated for the first time the association between the functional MIF polymorphisms and BLEL of lacrimal gland. Our results suggested that MIF-173 G to C mutations played an insidious role in susceptibility of BLEL of lacrimal gland, and plasma MIF expression. Further studies are still needed to deeply reveal the mechanism of its mighty function.
